Jan 04, 2023 8:30am EST Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
Dec 14, 2022 8:30am EST Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
Nov 08, 2022 4:00pm EST Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
Nov 02, 2022 8:30am EDT Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
Nov 01, 2022 8:30am EDT Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
Sep 15, 2022 8:30am EDT Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
Sep 07, 2022 8:30am EDT Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
Aug 16, 2022 8:30am EDT Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
Aug 12, 2022 9:30am EDT Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
